The correlation between sclerostin and bone mineral density in renal transplant recipients
The correlation between sclerostin and bone mineral density in renal transplant recipients
复制标题
DOI：
10.1016/j.nefro.2020.04.009
复制
发表时间：
2020-09-01
期刊：
影响因子：
2.6
通讯作者：
Okten, Sarper
中科院分区：
文献类型：
--
作者：
Coban, Melahat;Okten, Sarper
简介：硬化蛋白是一种由骨细胞合成的抗合成代谢蛋白，可能通过抑制骨形成引起骨质疏松症。我们的研究的目的是探讨sclerostin和骨密度（BMD）减少肾移植受者（RTRs）与超过1年transplantation.Material和方法的相关性：本横断面研究进行了80例（38（47.5%）男性/42（52.5%）女性）RTRs，平均年龄为44.68 +/- 10.39岁。将患者与年龄和性别匹配的40名健康人对照组进行比较。采用双能X线骨密度仪测量骨密度。结果：硬化蛋白的平均值为3.77 ± 0.3 pg/mL，健康人为3.81 ± 0.21 pg/mL。股骨转子（FT）（FT-T）、股骨颈（FN）（FN-T）、腰椎（L1 -4）（L1 -4-T）的平均T评分分别为-0.81 ± 0.86、-1.08 ± 1.09和-0.8 ± 1.2。FT（FT-Z）、FN（FN-Z）、L1-4（L1-4-Z）的平均Z评分分别为-0.6 +/- 0.73、-0.32 +/- 0.9和-0.54 +/- 1.13。患者的FT-Z和L1-4-Z低于健康受试者（分别为p = 0.009，p = 0.021）。血清肌酐（P < 0.001）、全段甲状旁腺素（P < 0.001）高于健康人，血磷（P < 0.001）低于健康人。log 10 sclerostin>3.84 pg/mL的患者的FT-T（p = 0.040）、FT-Z、FN-T（p = 0.018）、FN-Z（p = 0.006）高于log 10 sclerostin =3.84 pg/mL的患者。log 10 sclerostin与FN-T（r =-0.296，p = 0.009）和FN-Z（r =-0.269，p = 0.019）之间存在显著相关性。在线性回归分析中，高sclerostin被发现与男性性别，低FN-T和低FN-Z独立于其他危险factors.Conclusion：sclerostin的水平可以预测减少股骨近端BMD和发展的矿物质和骨紊乱的RTRs。RTR和健康个体之间的硬化素水平没有差异。由Elsevier Espana出版，S.L.U.代表西班牙毒品学协会
Introduction: Sclerostin is an anti-anabolic protein synthesized by osteocytes that may cause osteoporosis by inhibiting bone formation. The aim of our study was to investigate the correlation between sclerostin and bone mineral density (BMD) reduction in renal transplant recipients (RTRs) with more than 1 year after transplantation.Material and methods: This cross-sectional study was conducted on 80 patients (38 (47.5%) male/42 (52.5%) female) RTRs with a mean age of 44.68 +/- 10.39 years. Patients were compared with an age and sex-matched control group of 40 healthy individuals. BMD was measured by dual-energy X-ray absorptiometry. The levels of sclerostin were determined using enzyme-linked immunosorbent assay.Results: The mean sclerostin was 3.77 +/- 0.3 pg/mL in patients and 3.81 +/- 0.21 pg/mL in healthy individuals. The mean T score of femoral trochanter (FT) (FT-T), femoral neck (FN) (FN-T), lumbar vertebrae (L1-4) (L1-4-T) were-0.81 +/- 0.86,-1.08 +/- 1.09 and-0.8 +/- 1.2, respectively. The mean Z score of FT (FT-Z), FN (FN-Z), L1-4 (L1-4-Z) were-0.6 +/- 0.73,-0.32 +/- 0.9 and-0.54 +/- 1.13, respectively. FT-Z and L1-4-Z were lower in patients than healthy subjects (p = 0.009, p = 0.021 respectively). Serum creatinine (p < 0.001), intact parathyroid hormone (p < 0.001) were higher and phosphate (p < 0.001), was lower in patients than healthy subjects. Patients with a log10 sclerostin of >3.84 pg/mL had higher FT-T (p = 0.040), FT-Z, FN-T (p = 0.018), FN-Z (p = 0.006) than those with a log10 sclerostin of =3.84 pg/mL. There was a significant correlation between log10 sclerostin and FN-T (r =-0.296, p = 0.009) and FN-Z (r =-0.269, p = 0.019). In linear regression analysis, high sclerostin was found to be correlated with male gender, lower FN-T and lower FN-Z independently of other risk factors.Conclusion: The levels of sclerostin can predict reduction of proximal femur BMD and development of mineral and bone disorder in RTRs. There was no difference in sclerostin levels between RTRs and healthy individuals. Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Nefrologia.